ACRO BIOMEDICAL CO., LTD.
Datakwaliteit: 100%
ACBM
OTC
Services
Amusement & Recreation
€ 0,03
€ 0,00
(0,00%)
Marktkapitalisatie: 1,56 M
Prijs
€ 0,03
Marktkapitalisatie
1,56 M
Dagbereik
€ 0,03 — € 0,03
52-Weeksbereik
€ 0,00 — € 0,10
Volume
66
Openen € 0,03
50D / 200D Gem.
€ 0,02
11,11% above
50D / 200D Gem.
€ 0,01
202,33% above
Quick Summary
Belangrijkste Punten
Negative free cash flow of -196.302,0
Groei
Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A
Kwaliteit
Return on Equity
N/A
ROICN/A
Net MarginN/A
Op. MarginN/A
Veiligheid
Debt / Equity
N/A
Current Ratio0,01
Interest CoverageN/A
Waardering
PE (TTM)
-15,43
Onder sectorgemiddelde (-1,17)
P/B RatioN/A
EV/EBITDAN/A
Dividend YieldN/A
Koershistorie
Financiële Trends
Sectorvergelijking
vs Services sector mediaan (502 peers)
Sectorvergelijking
vs Services sector mediaan (502 peers)| Metriek | Aandeel | Sector Mediaan |
|---|---|---|
| P/E | -15,4 | -1,2 |
| P/B | — | 1,4 |
| ROE % | — | -15,7 |
| Net Margin % | — | -18,3 |
| Rev Growth 5Y % | — | 4,2 |
| D/E | — | 0,4 |
All Fundamental Metrics
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | N/A | Revenue Growth (3Y) | N/A |
| Earnings Growth (1Y) | N/A | Earnings Growth (3Y) | N/A |
| Revenue Growth (5Y) | N/A | Earnings Growth (5Y) | N/A |
| Profitability | |||
| Revenue (TTM) | 0,0 | Net Income (TTM) | -101.146,0 |
| ROE | N/A | ROA | -351,20% |
| Gross Margin | N/A | Operating Margin | N/A |
| Net Margin | N/A | Free Cash Flow (TTM) | -196.302,0 |
| ROIC | N/A | FCF Growth (3Y) | N/A |
| Safety | |||
| Debt / Equity | N/A | Current Ratio | 0,01 |
| Interest Coverage | N/A | Asset Turnover | 0,00 |
| Working Capital | -432.619 | Tangible Book Value | -432.619 |
| Dividends | |||
| Dividend Yield | N/A | Payout Ratio | N/A |
| Dividend Growth (3Y) | N/A | Dividend Growth (5Y) | N/A |
| Consecutive Div Years | N/A | ||
| Valuation | |||
| P/E Ratio | -15,43 | Forward P/E | N/A |
| P/B Ratio | N/A | P/S Ratio | N/A |
| PEG Ratio | N/A | Forward PEG | N/A |
| EV/EBITDA | N/A | Fwd EV/EBITDA | N/A |
| Forward P/S | N/A | Fwd Earnings Yield | N/A |
| FCF Yield | -12,57% | ||
| Market Cap | 1,56 M | Enterprise Value | 1,56 M |
| Per Share | |||
| EPS (Diluted TTM) | 0,00 | Revenue / Share | 0,00 |
| FCF / Share | 0,00 | OCF / Share | 0,00 |
| EPS CAGR (1Y) | N/A | EPS CAGR (5Y) | N/A |
| EPS CAGR (10Y) | N/A | ||
| Efficiency | |||
| CapEx / Revenue | N/A | FCF Conversion | 194,08% |
| SBC-Adj. FCF | N/A | Growth Momentum | N/A |
Income Statement
Annual, most recent first
Income Statement
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 0,0 | 0,0 | 0,0 | 658.500,0 | — |
| Net Income | -101.146,0 | -42.297,0 | -8,81 M | -15,87 M | -7,70 M |
| EPS (Diluted) | 0,00 | 0,00 | -0,15 | — | — |
| Gross Profit | — | — | 0,0 | 140.500,0 | 259.500,0 |
| Operating Income | -154.024,0 | -37.958,0 | -8,80 M | -15,87 M | -7,69 M |
| EBITDA | — | — | — | — | — |
| R&D Expenses | — | 0,0 | 4,79 M | 10,08 M | — |
| SG&A Expenses | 154.024,0 | 37.958,0 | 3,52 M | 5,93 M | 2,67 M |
| D&A | — | — | — | — | — |
| Interest Expense | — | — | 3.206,0 | 358,0 | 893,0 |
| Income Tax | 0,0 | 0,0 | 0,0 | 0,0 | 0,0 |
Balance Sheet
Annual, most recent first
Balance Sheet
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 14.098,0 | 31.974,0 | 58.459,0 | 687.486,0 | 761.077,0 |
| Total Liabilities | — | 326.946,0 | 315.473,0 | 201.116,0 | 117.370,0 |
| Shareholders' Equity | -386.964,0 | -294.972,0 | -257.014,0 | 486.370,0 | 643.707,0 |
| Total Debt | — | — | — | — | — |
| Cash & Equivalents | — | — | — | — | — |
| Current Assets | 14.098,0 | 5.076,0 | 1.626,0 | 657.537,0 | 706.415,0 |
| Current Liabilities | 401.062,0 | 326.946,0 | 288.575,0 | 201.116,0 | 91.651,0 |
{"event":"ticker_viewed","properties":{"ticker":"ACBM","listing_kind":"stock","pathname":"/stocks/acbm","exchange":"OTC","country":"US"}}